

**EISAI TO PRESENT LATEST DATA ON ERIBULIN  
AT 39TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting the latest clinical data on its in-house developed halichondrin class microtubule dynamics inhibitor eribulin mesylate (product name: Halaven<sup>®</sup>, "eribulin") will be presented